NRG Energy Inc vs Twist Bioscience Corp — how do they compare? NRG Energy Inc trades at $121.85 (market cap $24.83B), while Twist Bioscience Corp trades at $124.4 (market cap $7.72B). The key difference: NRG Energy Inc is far larger — about 3.2× Twist Bioscience Corp's market cap, and NRG Energy Inc pays a 1.61% dividend while Twist Bioscience Corp pays none. Which is the better fit depends on your goals.
| NRG | TWST | |
|---|---|---|
Market Cap | $24.83B | $7.72B |
Sector | Utilities | Health |
52-Week High | $184.03 | $124.88 |
52-Week Low | $117.04 | $24.16 |
Enterprise Value | $48.79B | $7.65B |
Dividend Yield | 1.61% | — |
Signals from Pluang's Aura AI — not financial advice
NRG Energy trades at $118.91, down 0.66% today, with a bearish technical signal. Recent Q2 2026 earnings missed estimates, but revenue grew 11% year-over-year. The company is expanding with a 1.2 GW Texas data-center power project, targeting long-term EBITDA growth. Valuation metrics show a P/E of 30.76 and P/S of 0.72, with strong ROE at 26.77% but modest net income margin of 2.56%. Cash flow trends are volatile, with 2025 net cash flow at $3.83B but a projected decline in 2026.
Outlook: Growth driven by data-center demand and strategic acquisitions offers upside, but high debt and earnings misses pose risks. Analyst consensus is bullish with a $207.83 price target, though technical weakness and rising interest costs require caution. Key opportunities include hyperscaler partnerships, while risks involve leverage and execution challenges.
TWST is trading at $124.88, up 7.96% in the last 24 hours, near its pivot point of $121 with resistance at $129. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Revenue growth is robust, with fiscal 2026 Q3 revenue up 23% year-over-year to $118.4 million, but the company remains unprofitable with a net income margin of -31.66% and negative cash flow from operations. Recent news highlights an upsized $300 million public offering and expansion in AI-driven drug discovery.
The outlook for TWST is mixed; bullish analyst sentiment and AI growth potential are offset by persistent losses and high valuation multiples. Investment opportunity lies in sustained revenue expansion and path to profitability, but risks include cash burn, competitive pressures, and execution challenges in scaling operations. The stock's current price exceeds the consensus target of $106.14, suggesting limited near-term upside based on fundamentals.
Trailing returns across standard periods
NRG Energy is one of the largest retail energy providers in the U.S., with 7 million customers, including its 2021 acquisition of Direct Energy. It also is one of the largest U.S. independent power producers, with 16 gigawatts of nuclear, coal, gas, and oil power generation capacity primarily in Texas. Since 2018, NRG has divested its 47% stake in NRG Yield, among other renewable energy and conventional generation investments. NRG exited Chapter 11 bankruptcy as a stand-alone entity in December 2003.
Read more on NRG →Twist Bioscience Corp is a synthetic biology company. It develops a disruptive DNA synthesis platform to industrialize the engineering of biology. The company's DNA synthesis platform utilizes a proprietary semiconductor-based synthetic DNA manufacturing process that synthesizes DNA on silicon instead of on traditional well plastic plates to enable the production of high-quality synthetic DNA faster and affordable as well as overcomes inefficiencies. Powering cost-effective, rapid high-throughput synthesis, it enables researchers to rapidly realize opportunities ahead. Geographically, it derives a majority of revenue from the United States.
Read more on TWST →